Treatment of Dravet Syndrome
Open Access
- 6 June 2016
- journal article
- review article
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- Vol. 43 (S3) , S13-S18
Abstract
Dravet syndrome is among the most challenging electroclinical syndromes. There is a high likelihood of recurrentstatus epilepticus; seizures are medically refractory; and patients have multiple co-morbidities, including intellectual disability, behaviour and sleep problems, and crouch gait. Additionally, they are at significant risk of sudden unexplained death. This review will focus predominantly on the prophylactic medical management of seizures, addressing both first-line therapies (valproate and clobazam) as well as second-line (stiripentol, topiramate, ketogenic diet) or later options (levetiracetam, bromides, vagus nerve stimulation). Sodium channel agents—including carbamazepine, oxcarbazepine, phenytoin and lamotrigine—should be avoided, as they typically exacerbate seizures. Several agents in development may show promise, specifically fenfluramine and cannabidiol, but they need further evaluation in randomized, controlled trials. In addition to prophylactic treatment, all patients need home-rescue medication and astatus epilepticusprotocol that can be carried out in their local hospital. Families must be counselled on non-pharmacologic strategies to reduce seizure risk, including avoidance of triggers that commonly induce seizures (including hyperthermia, flashing lights and patterns). In addition to addressing seizures, holistic care for a patient with Dravet syndrome must involve a multidisciplinary team that includes specialists in physical, occupational and speech therapy, neuropsychology, social work and physical medicine.Keywords
This publication has 42 references indexed in Scilit:
- Vagus nerve stimulation for drug‐resistant epilepsy: A European long‐term study up to 24 months in 347 childrenEpilepsia, 2014
- Encephalopathy in children with Dravet syndrome is not a pure consequence of epilepsyOrphanet Journal of Rare Diseases, 2013
- Effect of Vagus Nerve Stimulation in an Adult Patient with Dravet Syndrome: Contribution to Sudden Unexpected Death in Epilepsy Risk Reduction?European Neurology, 2012
- Dravet syndrome: Seizure control and gait in adults with different SCN1A mutationsEpilepsia, 2012
- Nonpharmacologic treatments of Dravet syndrome: Focus on the ketogenic dietEpilepsia, 2011
- Vagus nerve stimulation for refractory epilepsy in children: More to VNS than seizure frequency reductionEpilepsia, 2009
- Vagus nerve stimulation in pediatric epileptic syndromesSeizure: European Journal of Epilepsy, 2009
- Efficacité et tolérance à long terme du stiripentol dans le traitement de l’épilepsie myoclonique sévère du nourrisson (syndrome de Dravet)Archives de Pédiatrie, 2002
- Topiramate as add-on drug in children, adolescents and young adults with Lennox-Gastaut syndrome: an Italian multicentric studyEpilepsy Research, 2002
- Topiramate in the treatment of severe myoclonic epilepsy in infancySeizure: European Journal of Epilepsy, 2000